5N5C

NMR solution structure of the TSL2 RNA hairpin


Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 400 
  • Conformers Submitted: 40 
  • Selection Criteria: structures with the lowest energy 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes.

Garcia-Lopez, A.Tessaro, F.Jonker, H.R.A.Wacker, A.Richter, C.Comte, A.Berntenis, N.Schmucki, R.Hatje, K.Petermann, O.Chiriano, G.Perozzo, R.Sciarra, D.Konieczny, P.Faustino, I.Fournet, G.Orozco, M.Artero, R.Metzger, F.Ebeling, M.Goekjian, P.Joseph, B.Schwalbe, H.Scapozza, L.

(2018) Nat Commun 9: 2032-2032

  • DOI: 10.1038/s41467-018-04110-1

  • PubMed Abstract: 
  • Modification of SMN2 exon 7 (E7) splicing is a validated therapeutic strategy against spinal muscular atrophy (SMA). However, a target-based approach to identify small-molecule E7 splicing modifiers has not been attempted, which could reveal novel th ...

    Modification of SMN2 exon 7 (E7) splicing is a validated therapeutic strategy against spinal muscular atrophy (SMA). However, a target-based approach to identify small-molecule E7 splicing modifiers has not been attempted, which could reveal novel therapies with improved mechanistic insight. Here, we chose as a target the stem-loop RNA structure TSL2, which overlaps with the 5' splicing site of E7. A small-molecule TSL2-binding compound, homocarbonyltopsentin (PK4C9), was identified that increases E7 splicing to therapeutic levels and rescues downstream molecular alterations in SMA cells. High-resolution NMR combined with molecular modelling revealed that PK4C9 binds to pentaloop conformations of TSL2 and promotes a shift to triloop conformations that display enhanced E7 splicing. Collectively, our study validates TSL2 as a target for small-molecule drug discovery in SMA, identifies a novel mechanism of action for an E7 splicing modifier, and sets a precedent for other splicing-mediated diseases where RNA structure could be similarly targeted.


    Organizational Affiliation

    Pharmaceutical Biochemistry Group, School of Pharmaceutical Sciences, University of Lausanne and University of Geneva, Rue Michel-Servet 1, 1211, Geneva, Switzerland. amparo.garcialopez@unige.ch.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsLengthOrganism
RNA (19-MER)A19Homo sapiens
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 400 
  • Conformers Submitted: 40 
  • Selection Criteria: structures with the lowest energy 

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
European Union261863
iNEXT - European Union Horizon 2020 programme653706
European Union261572
LOEWE program SynChemBioGermany--
German Research FoundationGermany--
European Molecular Biology OrganizationALTF 253-2012
SMA Europe17623 and 19243
Schmidheiny FoundationSwitzerland--
Generalitat Valenciana - Santiago Grisolia PhD programSpain--

Revision History 

  • Version 1.0: 2018-03-14
    Type: Initial release
  • Version 1.1: 2018-06-06
    Type: Data collection, Database references